ADReCS

Pharmaceutical Information

Drug Name	Carboplatin
Drug ID	BADD_D00364
Description	Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage	Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]
Marketing Status	approved
ATC Code	L01XA02
DrugBank ID	DB00958
KEGG ID	D01363
MeSH ID	D016190
PubChem ID	426756
TTD Drug ID	D0X7HM
NDC Product Code	0703-4239; 55150-386; 63323-172; 68083-191; 63592-0271; 61703-339; 0703-4244; 0703-4246; 72659-863; 50742-447; 69448-005; 61703-600; 55150-334; 61703-262; 61703-360; 71288-100; 49812-0010; 16729-295; 55150-333; 61703-150; 68083-193; 68554-0084; 68083-190; 68083-192; 53104-7570; 54875-0002; 50742-448; 55150-335; 0703-4248
UNII	BG3F62OND5
Synonyms	Carboplatin \| cis-Diammine(cyclobutanedicarboxylato)platinum II \| CBDCA \| Paraplatin \| Paraplatine \| Platinwas \| Ribocarbo \| Carboplat \| Neocarbo \| Carbosin \| Carbotec \| Ercar \| JM-8 \| JM 8 \| JM8 \| Nealorin \| NSC-241240 \| NSC 241240 \| NSC241240 \| Blastocarb

Chemical Information

Molecular Formula	C6H12N2O4Pt
CAS Registry Number	41575-94-4
SMILES	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
General physical health deterioration	08.01.03.018	0.001455%		Not Available
Left ventricular dysfunction	02.04.02.011	0.000168%
Tumour haemorrhage	24.07.01.028; 16.32.03.008	0.000112%
Shock haemorrhagic	24.06.02.014; 14.05.05.003	0.000280%		Not Available
Anal sphincter atony	17.05.02.009; 07.03.01.003	0.000504%		Not Available
Idiosyncratic drug reaction	08.06.01.002	0.000112%		Not Available
Subileus	07.13.01.004	0.000224%		Not Available
Lupus-like syndrome	10.04.03.003; 23.03.02.004; 15.06.02.004	0.000112%		Not Available
Deep vein thrombosis	24.01.02.003	0.001623%		Not Available
Lacunar infarction	24.04.06.009; 17.08.01.016	0.000168%		Not Available
Cardiopulmonary failure	22.02.06.004; 02.05.01.004	0.000168%		Not Available
Madarosis	23.02.02.004; 06.06.04.010	0.000358%		Not Available
Central nervous system lesion	17.02.10.011	0.000280%		Not Available
Systemic inflammatory response syndrome	24.06.03.008; 10.02.01.008; 08.01.05.005	0.000168%		Not Available
Malignant neoplasm progression	16.16.01.005	0.006548%		Not Available
Acute coronary syndrome	24.04.04.011; 02.02.02.015	-	-	Not Available
Conjunctival hyperaemia	06.04.01.004	0.000112%		Not Available
Metastases to peritoneum	16.22.02.008; 07.21.03.003	0.000280%		Not Available
Cytokine release syndrome	10.02.01.010	0.000112%
Metabolic syndrome	05.06.02.007; 24.08.02.014; 14.06.02.007	0.000112%		Not Available
Ear pruritus	04.03.01.011	0.000302%		Not Available
Eye pruritus	06.04.05.006	0.000716%		Not Available
Catheter site erythema	23.03.06.014; 12.07.02.003; 08.02.02.003	0.000112%		Not Available
Drug tolerance decreased	08.06.01.024	0.000224%		Not Available
Musculoskeletal discomfort	15.03.04.001	-	-	Not Available
Inappropriate antidiuretic hormone secretion	14.05.07.001; 05.03.03.001	0.001399%		Not Available
Febrile bone marrow aplasia	01.03.03.007; 08.05.02.005	0.000783%		Not Available
Injection site swelling	12.07.03.018; 08.02.03.017	-	-	Not Available
Infusion site pain	12.07.05.002; 08.02.05.014	0.000392%		Not Available
Infusion site swelling	12.07.05.003; 08.02.05.002	0.000224%		Not Available

The 15th Page First Pre 15 16 17 18 19 Next Last Total 21 Pages